MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
7.22
-0.70 (-8.84%)
Apr 29, 2025, 10:41 AM EDT - Market open
MiNK Therapeutics Employees
MiNK Therapeutics had 23 employees as of December 31, 2024. The number of employees decreased by 8 or -25.81% compared to the previous year.
Employees
23
Change (1Y)
-8
Growth (1Y)
-25.81%
Revenue / Employee
n/a
Profits / Employee
-$468,904
Market Cap
28.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23 | -8 | -25.81% |
| Dec 31, 2023 | 31 | -6 | -16.22% |
| Dec 31, 2022 | 37 | 4 | 12.12% |
| Dec 31, 2021 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
INKT News
- 5 weeks ago - MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress - GlobeNewsWire
- 2 months ago - MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - GlobeNewsWire
- 2 months ago - MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting - GlobeNewsWire
- 2 months ago - MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting - GlobeNewsWire
- 3 months ago - MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - GlobeNewsWire
- 4 months ago - MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting - GlobeNewsWire
- 5 months ago - MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha